Answers are grounded in this paper and cite their sources.
Based on network pharmacology and experimental validation, our study indicated that HLJDD exerted anti-AS effect through upregulating CD31 expression and reducing the expression of ICAM-1 and RAM-11. HLJDD may be a potential therapeutic drug to the prevention of AS.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: